What Is the EU Manufacturing and Importation Authorisation (MIA)?

EU Manufacturing and Importation Authorisation (MIA) Authorisation required for companies manufacturing or importing medicinal products in the EU. The MIA is the formal licence issued by a national competent authority that allows an organization to manufacture, import or perform specific operations on human or veterinary medicinal products in a particular Member State.

The MIA is issued under the framework established by EU pharmaceutical law and is granted only after the regulator is satisfied that the applicant has the premises, personnel, procedures and quality systems required to produce or import medicines in compliance with Good Manufacturing Practice (GMP) and relevant national requirements. The scope of an MIA is explicit: it lists permitted activities (such as manufacture, packaging, labelling, batch release, or importation) and attaches conditions the holder must meet.

Why The MIA Exists

Regulators issue MIAs to ensure that companies dealing with medicinal products operate to standards that protect patient safety and product quality. The licence is a gatekeeper: without it, manufacturing or importing medicinal products into the EU is illegal. The MIA aligns manufacturing and import controls across Member States, helps regulators plan inspections and enforces a single standard: compliance with GMP plus any additional national conditions.

What The Authorisation Typically Covers

• Activities: The MIA lists permitted operations such as manufacture, labelling, secondary packaging, assembly and importation.
• Site Details: The licence names the physical site(s) where activities may be performed.
• Responsible Persons: Key roles the holder must appoint (for example, Qualified Person functions under EU law) and their responsibilities.
• Conditions And Restrictions: Any limitations, such as specific dosage forms, special storage conditions, or conditions tied to GMP certification.

How An MIA Is Obtained

Application procedures vary by Member State but follow the same legal basis. An applicant submits a dossier to the national competent authority containing site details, organisational structure, quality systems, standard operating procedures (SOPs), premises layout, equipment lists and evidence of personnel competence. Inspectors usually carry out an on-site GMP inspection before granting a licence or may review existing GMP certificates. Import authorisations include checks on the proposed import chain, customs declarations and contracts with manufacturers in third countries.

Inspections, GMP And The Qualified Person

GMP compliance is central. National authorities rely on EudraLex Volume 4 (GMP) standards or recognized inspection schemes (for example PIC/S equivalence) when assessing an MIA application. The licence holder must ensure a Qualified Person (QP) or equivalent authorised individual certifies each batch released for the EU market. For importers, documentation proving GMP compliance at the foreign manufacturer is expected and may require a valid GMP certificate or inspection report.

How It Varies Between Member States

Because MIAs are issued by national authorities, the form, fees, processing times and detailed evidence requirements differ across Member States. Some regulators publish detailed application checklists and timelines; others handle requests on a case-by-case basis. For companies operating in several Member States, this can mean multiple MIAs (one per site / country) or separate notifications if operations are centralised. Coordination between MIA holders and the marketing-authorisation holder is often necessary when responsibilities are split across jurisdictions.

Who Needs An MIA

• Manufacturers: Any company that physically produces bulk drug substance, formulates, fills, or packages medicinal products intended for the EU market.
• Importers: Businesses bringing finished medicinal products or active substances into the EU from third countries.
• Contract Manufacturers And CMOs: Contract organisations providing manufacturing services on behalf of marketing-authorisation holders when operations occur in the EU.

Practical Example

A contract manufacturing organisation (CMO) in Spain wants to add a sterile injectable to its permitted activities. The CMO submits an updated site master file, SOPs for sterile production, evidence of staff training, and the cleanroom validation data to Spain's competent authority. After a GMP inspection confirms compliance, the authority updates the MIA to include sterile injectables and lists the new manufacturing line under permitted activities.

Tips For Applicants

• Prepare GMP Evidence Early: Ensure site master files, validation records and personnel qualifications are complete before applying.
• Engage With The Regulator: Use pre-application meetings where available to clarify dossier expectations and timelines.
• Align With Marketing-Authorisation Holders: Confirm responsibilities for release, stability data and pharmacovigilance before submitting applications.

In short, the EU Manufacturing and Importation Authorisation (MIA) is the national licence that permits the manufacture or import of medicinal products in EU Member States. It ties legal permission to demonstrable GMP-compliant facilities, qualified personnel and documented quality systems — a necessary control to protect product quality and patient safety.